Investors evaluating medical technology often weigh established scale against earlier-stage growth potential. This stock comparison examines CLPT, a developing player in neurosurgical navigation and cell-and-gene therapy delivery, against ISRG, a global pioneer in robotic-assisted surgery. The two companies operate in adjacent areas of healthcare technology yet represent very different profiles in terms of size, maturity, and profitability. Traders focused on relative performance and market positioning may find this contrast useful, as it highlights the trade-offs between a high-margin industry leader and a smaller, faster-growing company pursuing a specialized opportunity in the central nervous system.
CLPT, or ClearPoint Neuro, develops devices, software, and services that enable precise navigation to the brain and spine, including its flagship ClearPoint Neuro Navigation System. The company also partners with biotech firms to support direct delivery of therapeutics to the central nervous system in preclinical studies and clinical trials. In recent quarters, CLPT has shown accelerating revenue growth, reporting about 20% comparable sales growth in the fourth quarter of 2025 and full-year 2025 revenue of roughly $37 million, up from $31.4 million in 2024. The company completed its acquisition of IRRAS Holdings in November 2025, adding the IRRAflow product line to its neurosurgery portfolio. Management guided to 2026 revenue between $54 million and $60 million. Despite this momentum, CLPT remains unprofitable, posting a 2025 net loss of about $25.5 million, and holds cash of approximately $45.9 million as it invests in infrastructure ahead of anticipated commercialization of neuro cell-and-gene therapies.
ISRG, or Intuitive Surgical, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery, best known for its da Vinci surgical systems and the Ion endoluminal system. The company's recent market activity has been defined by strong procedure growth and a large-scale product cycle around its newest da Vinci 5 platform. Full-year 2025 revenue grew approximately 21% to about $10.06 billion, with roughly 3.15 million da Vinci procedures performed, up about 18% year over year. Fourth-quarter revenue of about $2.87 billion reflected higher system placements and recurring instrument and accessory sales. For 2026, ISRG guided da Vinci procedure growth of 13% to 15%, a deceleration from 2025. The company's scale, installed base of more than 11,000 da Vinci systems, and recurring revenue model support strong profitability, though its premium valuation and rising competition in surgical robotics have shaped recent sentiment.
For traders seeking a systematic view of stocks like CLPT and ISRG, Tickeron's Trending AI Robots page offers a curated selection of AI trading bots. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and sets of securities they monitor. Rather than listing every available bot, the Trending AI Robots section highlights only the bots considered most suitable for current market conditions. Explore the page to see which automated strategies are currently gaining traction and how their approaches might apply to names across the healthcare technology sector.
The clearest contrast between these two stocks is scale and stage. ISRG generates roughly $10 billion in annual revenue with strong operating margins and a diversified, recurring income stream, whereas CLPT produces about $37 million in annual revenue and is still funding its path to profitability. In growth drivers, ISRG relies on procedure volume, system placements, and upgrades such as the da Vinci 5, while CLPT depends on disposables, neurosurgery adoption, and the long-term commercialization of gene-and-cell therapies by its biotech partners. Risk profiles also differ: CLPT carries execution, integration, and financing risk as a small-cap, whereas ISRG faces a high valuation, a decelerating procedure-growth outlook, and intensifying competition. Sector exposure is related but not identical, with ISRG concentrated in surgical robotics and CLPT in neuro-navigation and drug delivery.
Based on observable trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor ISRG in the current environment. The company's established profitability, recurring revenue base, large installed system footprint, and consistent procedure growth provide a more stable and verifiable trend than CLPT's earlier-stage, unprofitable profile. That said, CLPT presents a higher-growth, higher-risk opportunity tied to emerging cell-and-gene therapy adoption, which may appeal to more speculative strategies. The AI assessment is probabilistic rather than definitive, and relative positioning could shift as new catalysts, earnings reports, or shifts in sector sentiment emerge.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for CLPT moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 84 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 49 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CLPT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLPT entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 217 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (24.345) is slightly higher than the industry average of (4.142). P/E Ratio (-7.288) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The RSI Indicator for ISRG moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 211 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
ISRG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 169 of 265 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ISRG as a result. In 48 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for ISRG turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 31 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
ISRG moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. ISRG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.805) is normal, around the industry mean (4.964). P/E Ratio (51.222) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
CLPT | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 46 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 82 | |
SMR RATING 1..100 | 100 | 51 | |
PRICE GROWTH RATING 1..100 | 84 | 57 | |
P/E GROWTH RATING 1..100 | 13 | 81 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLPT's Valuation (46) in the null industry is somewhat better than the same rating for ISRG (79) in the Medical Specialties industry. This means that CLPT’s stock grew somewhat faster than ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (82) in the Medical Specialties industry is in the same range as CLPT (100) in the null industry. This means that ISRG’s stock grew similarly to CLPT’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for CLPT (100) in the null industry. This means that ISRG’s stock grew somewhat faster than CLPT’s over the last 12 months.
ISRG's Price Growth Rating (57) in the Medical Specialties industry is in the same range as CLPT (84) in the null industry. This means that ISRG’s stock grew similarly to CLPT’s over the last 12 months.
CLPT's P/E Growth Rating (13) in the null industry is significantly better than the same rating for ISRG (81) in the Medical Specialties industry. This means that CLPT’s stock grew significantly faster than ISRG’s over the last 12 months.
| CLPT | ISRG | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 84% | 3 days ago 69% |
| Stochastic ODDS (%) | 3 days ago 86% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 61% |
| MACD ODDS (%) | 3 days ago 89% | 3 days ago 74% |
| TrendWeek ODDS (%) | 3 days ago 86% | 3 days ago 64% |
| TrendMonth ODDS (%) | 3 days ago 85% | 3 days ago 70% |
| Advances ODDS (%) | 25 days ago 79% | 19 days ago 67% |
| Declines ODDS (%) | 3 days ago 87% | 3 days ago 60% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 64% |
| Aroon ODDS (%) | 3 days ago 86% | 3 days ago 64% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLPT’s FA Score shows that 1 FA rating(s) are green while ISRG’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLPT’s TA Score shows that 3 TA indicator(s) are bullish while ISRG’s TA Score has 5 bullish TA indicator(s).
CLPT (@Medical/Nursing Services) experienced а -18.51% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -10.04% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -11.44%. For the same industry, the average monthly price growth was -15.18%, and the average quarterly price growth was -18.29%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -7.82%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +4.34%.
CLPT is expected to report earnings on Mar 03, 2027.
ISRG is expected to report earnings on Jan 26, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-7.82% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | -5.47% | ||
| ICUI - CLPT | 57% Loosely correlated | -1.84% | ||
| ISRG - CLPT | 46% Loosely correlated | -2.01% | ||
| A - CLPT | 45% Loosely correlated | -2.83% | ||
| NVST - CLPT | 45% Loosely correlated | -1.55% | ||
| SMTI - CLPT | 43% Loosely correlated | -0.37% | ||
More | ||||